Red light therapy shows genuine promise for several types of nerve pain, though the strength of evidence varies depending on the specific condition. Trials in diabetic neuropathy, chemotherapy-induced neuropathy, and postherpetic neuralgia have reported meaningful pain reductions, and animal research suggests the therapy can accelerate nerve repair at a cellular level. The picture is more complicated than a simple yes or no, though, because the dose, wavelength, and type of nerve damage all shape whether the treatment helps, does nothing, or in rare cases makes things worse.
What Red Light Does Inside Nerve Tissue
Red and near-infrared light in the range of roughly 600 to 900 nanometers can penetrate skin and reach underlying tissue, where it gets absorbed by a component of the energy-production machinery inside cells. Specific wavelengths in this range are absorbed by a protein in the mitochondria called cytochrome c oxidase, and when that happens, cells ramp up their energy output. That boost in cellular energy appears to set off a chain of downstream effects: reduced inflammation, lower counts of immune cells driving the inflammatory response, and improved cellular repair.1The Royal Society. Near-infrared light increases ATP, extends lifespan and improves mobility in aged Drosophila melanogaster – Section: 1. Introduction One of the most consistently documented effects of this kind of light therapy is a broad reduction in inflammation across different tissue types, including the brain and spinal cord.2PubMed Central. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation
For nerve pain specifically, this matters because chronic inflammation is one of the main drivers of ongoing pain signaling. Damaged or irritated nerves often sit in an environment of persistent low-grade inflammation that keeps pain pathways activated long after the original injury. By dialing down that inflammatory environment, red light therapy may interrupt the cycle that keeps nerve pain going. It is worth noting that researchers usually call this “photobiomodulation” (PBM) rather than red light therapy, and the two terms refer to the same thing.
Diabetic Peripheral Neuropathy
Nerve damage from diabetes is one of the conditions where clinical evidence for red light therapy is strongest. The high blood sugar levels that come with diabetes gradually damage small nerve fibers, especially in the feet and hands, causing burning, tingling, numbness, and pain that often responds poorly to medication.
A randomized controlled trial in people with type 2 diabetes and peripheral neuropathy tested photobiomodulation therapy against standard care. Four weeks after treatment, the group receiving light therapy showed significant improvements across a range of measures: neuropathic pain scores dropped, protective sensation in the feet improved, neuropathic symptom questionnaire scores improved, and quality of life went up. The researchers also tracked biomarkers in the blood and found significant changes in neuron-specific enolase and calcitonin gene-related peptide, both of which are linked to nerve health and pain signaling.3PubMed. A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy The fact that both the subjective pain reports and the objective blood markers moved in the same direction strengthens the case that something real is happening, not just a placebo effect.
That said, this is still a relatively small body of research. Most diabetic neuropathy trials of red light therapy have enrolled dozens of people rather than hundreds or thousands, so while the direction of the evidence is encouraging, the kind of large-scale confirmation that would make this a standard recommendation has not arrived yet.
Chemotherapy-Induced Nerve Pain
Chemotherapy drugs like taxanes, platinum compounds, and vinca alkaloids frequently damage peripheral nerves as a side effect, causing numbness, tingling, pain, and loss of coordination in the hands and feet. This kind of neuropathy can persist for months or years after treatment ends, and the options for managing it are limited.
Research into photobiomodulation for chemotherapy-induced peripheral neuropathy (CIPN) is still early but pointing in a positive direction. A pilot trial called NEUROLIGHT tested light therapy on cancer patients or survivors dealing with CIPN and found that neuropathy symptoms and mobility both improved significantly over the treatment period. Pain scores also improved over time, with the group receiving a specific dose showing better pain relief than the comparison group.4PubMed Central. Evaluating the efficacy of photobiomodulation therapy in the management of chemotherapy-induced peripheral neuropathy: a pilot trial (NEUROLIGHT trial)
A separate review of the mechanisms involved suggests that light therapy in the near-infrared range has the ability to relieve allodynia, which is the painful sensation caused by touch that should not normally hurt. The proposed mechanism involves calming overactive sensory channels in the nerve and promoting nerve regeneration that restores normal sensory function.5Journal of Medical Radiation Oncology. Photobiomodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: Targeted Mechanisms and Optimized Strategies for Sensory Symptom Relief For people who have been told there is not much they can do about lingering chemo-related nerve symptoms, this represents a potentially useful option to discuss with their oncology team.
Postherpetic Neuralgia
Shingles, caused by the reactivation of the chickenpox virus, can leave behind a particularly stubborn form of nerve pain called postherpetic neuralgia. The virus damages nerve fibers during the active infection, and in some people the pain persists for months or years after the rash clears. It is notoriously difficult to treat, and standard medications like gabapentin or lidocaine patches provide only partial relief for many patients.
A pilot study of low-level laser therapy in postherpetic neuralgia patients produced striking results. Among 15 patients, 11 saw their pain scores drop to zero by the end of treatment, even though eight of those patients had started with severe pain. Three others saw their pain decrease to mild levels. The researchers followed up and found that patients had not experienced a recurrence of pain even months after completing therapy.6PubMed. Role of low-level laser therapy in post-herpetic neuralgia: a pilot study
Those results are impressive, but they come with the usual caveat of a small pilot study without a placebo control arm. People with severe chronic pain are highly susceptible to the placebo effect, and without a sham-light comparison group, it is hard to separate real therapeutic effects from the benefit of receiving attentive care over multiple sessions. Still, the magnitude of the improvement, with most patients going from severe to zero pain, is larger than what researchers typically see from placebo alone.
Trigeminal Neuralgia and Facial Nerve Pain
Trigeminal neuralgia involves sudden, severe, shock-like pain in the face, triggered by the trigeminal nerve. It can make everyday activities like eating, talking, or brushing teeth excruciating. The standard first-line treatment is the anticonvulsant carbamazepine, but some patients develop tolerance over time or cannot handle the side effects.
A review of the literature on low-level laser therapy for trigeminal neuralgia found that the treatment could provide pain relief without side effects, and noted it may be particularly helpful for patients who have become tolerant to drug therapy.7PubMed Central. The Effect of Low-level Laser Therapy on Trigeminal Neuralgia: A Review of Literature The trigeminal nerve runs relatively close to the surface in parts of the face, which may make it more accessible to light therapy than deeper nerves in the limbs or torso. The evidence here is still thin compared to diabetic neuropathy research, but the direction is consistent with what is seen in other nerve pain conditions.
Can Red Light Actually Regenerate Damaged Nerves?
Beyond simply reducing pain, there is an interesting question about whether red light therapy can help nerves physically repair themselves. A systematic review of photobiomodulation for peripheral nerve regeneration found evidence that the therapy increased Schwann cells, which are the cells that form the insulating sheath around nerve fibers and are critical for nerve repair. The treatment appeared to speed up and enhance nerve regeneration in studies where nerves had been experimentally damaged.8PubMed Central. Photobiomodulation Therapy (PBMT) in Peripheral Nerve Regeneration: A Systematic Review A separate study using near-infrared LEDs confirmed that nerve regeneration was promoted in the treatment group compared to controls.9PubMed. Effect of near-infrared light-emitting diodes on nerve regeneration
Most of this regeneration evidence comes from animal models where researchers can crush or cut a nerve and then track regrowth under a microscope. Whether the same degree of regeneration occurs in humans with long-standing nerve damage is less clear. But the biological plausibility is there: if red light boosts cellular energy production and reduces inflammation while also stimulating Schwann cell activity, you have three mechanisms working together to create a more favorable environment for nerve repair. For someone whose nerve pain stems from partial nerve damage rather than complete destruction, this offers at least a theoretical reason to think the therapy might address the underlying problem and not just mask the pain.
Why Getting the Dose Wrong Can Mean Getting No Results
One of the reasons red light therapy remains controversial despite positive results in many studies is that getting the dose right turns out to be surprisingly tricky. Researchers have repeatedly documented what is called a biphasic dose response: low levels of light stimulate healing and tissue repair, but higher levels can actually inhibit the same processes or have no effect at all.10PubMed Central. Biphasic dose response in low level light therapy This means that more is not better. Doubling the treatment time or cranking up the power does not double the benefit; it may erase it entirely.
This biphasic response has been a major source of confusion in the research literature. Some studies that reported no benefit from light therapy may have simply used too much or too little energy. The therapy’s history of mixed results led many clinicians to dismiss it, but the inconsistency appears to be at least partly a dosing problem rather than evidence that the therapy does not work.11PubMed Central. Biphasic dose response in low level light therapy – an update
Adding another layer of complexity, the amount of light that actually reaches the target nerve depends heavily on individual anatomy. A study of low-power laser therapy for carpal tunnel syndrome measured how much light was reflected back from patients’ wrists and found enormous variation: the reflection coefficient ranged from under 2% to over 54%.12PubMed Central. Low-power laser therapy for carpal tunnel syndrome: effective optical power In practical terms, that means two people receiving the exact same treatment might have very different amounts of light reaching their nerves. Skin color, tissue thickness, fat deposits, and even blood flow all affect penetration. This is a problem that clinical protocols have not fully solved, and it partly explains why some patients report dramatic relief while others notice nothing.
When Red Light Therapy Might Not Help
Not every study of red light and nerve function has found positive results. A study testing a cluster array of infrared and red LEDs on the superficial radial nerve found no significant differences in nerve conduction velocity or nerve peak latency between the treatment and control groups. The only measurable change was an increase in skin temperature at the treatment site.13PubMed Central. The Effect of Light Therapy on Superficial Radial Nerve Conduction Using a Clustered Array of Infrared Super luminous Diodes and Red Light Emitting Diodes This matters because it shows that red light therapy does not universally improve nerve function in healthy nerves; its benefits may be more specific to damaged or inflamed nerves where there is something going wrong that the therapy can correct.
There is also an important caveat about how the light is applied. Research has found that applying red light directly to the skin over a painful area can reduce pain in neuropathies, but shining the same wavelength of red light into the eyes has been reported to make migraine headaches worse and, in animal models, to actually create functional pain that was not there before.14PubMed Central. Mechanisms and Pathways of Pain Photobiomodulation: A Narrative Review The takeaway is that the same wavelength of light can have opposite effects depending on the route of delivery, which is a finding that should give pause to anyone tempted to assume that more exposure in more places equals more benefit.
What This Means for Home Devices
The consumer market for red light therapy panels, wraps, and handheld devices has exploded in recent years, and many of these products are marketed specifically for pain relief. The gap between what research clinics use and what you can buy online is significant, though. Clinical studies typically use carefully calibrated devices with known power outputs, specific wavelengths (often 660 nanometers for red and 810 to 850 nanometers for near-infrared), controlled treatment distances, and timed sessions. Consumer devices vary enormously in actual power output, and many do not deliver enough energy to reach deeper nerves.
The reflection and penetration variability documented in carpal tunnel research illustrates why buying a device and holding it against your skin is not the same as receiving a calibrated clinical treatment. If a consumer device delivers too little energy, it falls below the effective threshold. If it delivers too much (less likely with home devices, but possible with prolonged sessions), the biphasic response suggests it could be counterproductive. People who try a home device for nerve pain and notice nothing should not necessarily conclude that red light therapy does not work for them; they may have simply not delivered enough of the right wavelength to the right depth.
If you are considering trying red light therapy for nerve pain, a few practical points are worth keeping in mind. Look for devices that specify their wavelength output, ideally in the 630 to 670 nm range for red and 800 to 860 nm range for near-infrared. Check that the device lists its power density, which should be in line with what clinical studies have used. Start with shorter sessions rather than longer ones, given the biphasic response. And treat the area directly over the painful nerve rather than broadly irradiating a general area.
How It Compares to Standard Nerve Pain Medications
The most commonly prescribed medications for nerve pain include gabapentin, pregabalin, duloxetine, and tricyclic antidepressants. These drugs work, but often incompletely. A substantial percentage of patients get less than 50% pain reduction from any single drug, and side effects like drowsiness, dizziness, weight gain, and cognitive fog are common enough that many people stop taking them.
Red light therapy’s main advantage is its side effect profile, which in the studies reviewed is essentially nonexistent. No study in the sources reported significant adverse events from the therapy. For someone who cannot tolerate nerve pain medications, or who is already taking multiple drugs and does not want to add another, red light therapy occupies a useful niche as a non-pharmacological option that may provide additional relief. The postherpetic neuralgia pilot study is a good example of the potential upside: patients went from severe pain to no pain without taking any additional medication.6PubMed. Role of low-level laser therapy in post-herpetic neuralgia: a pilot study
The main disadvantage is the lack of large-scale, rigorously controlled trials. No regulatory body has approved red light therapy as a standard treatment for any form of nerve pain. Most of the evidence consists of small trials and pilot studies, and the dosing inconsistencies across studies make it hard to write clear clinical guidelines. This is a therapy where the biological rationale is strong, the early clinical results are encouraging, and the side effects are minimal, but the evidence base has not matured to the point where a neurologist would recommend it as a first-line treatment over established medications.
Conditions Where the Evidence Is Still Essentially Missing
While research has started to accumulate for diabetic neuropathy, chemotherapy-induced neuropathy, and postherpetic neuralgia, several common nerve pain conditions have barely been studied with red light therapy. Sciatica, which involves pain radiating down the leg from a compressed spinal nerve root, does not yet have controlled trials specifically testing photobiomodulation. Similarly, pudendal neuralgia (pelvic nerve pain), small fiber neuropathy from autoimmune causes, and idiopathic neuropathy where no cause can be identified all represent gaps in the research.
The anti-inflammatory mechanism suggests red light therapy could plausibly help in any of these conditions, since inflammation plays a role in most forms of nerve pain. But plausibility is not proof, and the dosing challenges become even more complicated when trying to reach deep nerves like the sciatic or pudendal nerves, which sit far beneath the surface. Until trials specific to these conditions exist, any benefit remains speculative. People with these forms of nerve pain who want to try red light therapy are not necessarily being irrational, given the low risk profile, but they should be clear-eyed about the fact that they are experimenting on themselves with limited guidance from the research.